| __timestamp | Bristol-Myers Squibb Company | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 8246000000 |
| Thursday, January 1, 2015 | 5001000000 | 9232000000 |
| Friday, January 1, 2016 | 5002000000 | 9366000000 |
| Sunday, January 1, 2017 | 4849000000 | 9672000000 |
| Monday, January 1, 2018 | 4551000000 | 9915000000 |
| Tuesday, January 1, 2019 | 4871000000 | 11402000000 |
| Wednesday, January 1, 2020 | 7661000000 | 11456000000 |
| Friday, January 1, 2021 | 7690000000 | 10975000000 |
| Saturday, January 1, 2022 | 7814000000 | 8372000000 |
| Sunday, January 1, 2023 | 7772000000 | 9385000000 |
| Monday, January 1, 2024 | 8414000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Bristol-Myers Squibb Company and GSK plc, two titans in the field, have shown distinct approaches over the past decade. From 2014 to 2023, GSK consistently reported higher SG&A expenses, peaking in 2020 with a 14% increase from 2014. In contrast, Bristol-Myers Squibb demonstrated a more conservative approach, with expenses rising by approximately 36% over the same period. Notably, 2022 marked a pivotal year where Bristol-Myers Squibb's expenses surpassed GSK's, indicating a strategic shift. This data highlights the dynamic strategies employed by these companies in response to market pressures and operational demands. As the industry evolves, understanding these financial maneuvers offers valuable insights into corporate efficiency and strategic planning.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Cost Insights: Breaking Down Bristol-Myers Squibb Company and GSK plc's Expenses
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and GSK plc
Breaking Down SG&A Expenses: GSK plc vs Viatris Inc.
Who Optimizes SG&A Costs Better? GSK plc or Bio-Techne Corporation
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights